Speakers
Prof. Dr. Malcolm BrennerBaylor College of Medicine (BCM), Houston/USA
Prof. Dr. Eric Gottwald, Karlsruher Institut für Technologie(KIT)
Prof. Dr. Peter Lang, Universitätsklinikum Tübingen
PD Dr. Uta Höpken, MDC Max-Delbrück-Centrum, Berlin
Prof. Dr. Michael Hudecek, Uniklinikum Würzburg
Dr. Armin Rehm, MDC Max-Delbrück-Centrum, Berlin
Prof. Dr. Dr. h.c. Christof Scheid, Uniklinik Köln
Prof. Dr. Marion Subklewe, LMU München
PD Dr. Simone Thomas, Universitätsklinikum Regensburg
PD Dr. Patrick Wuchter, Transfusionsmedizin,Universitätsmedizin Mannheim
Prof. Dr. Andreas Kulozik, Pädiatrische Onkologie, Zentrumfür Kinder- und Jugendmedizin, UniversitätsklinikumHeidelberg
Dr. Patrick DerigsPD Dr. Sascha DietrichProf. Dr. Peter DregerProf. Dr. Hartmut GoldschmidtProf. Dr. Carsten Müller-TidowDr. Tim SauerDr. Maria-Luisa SchubertPD Dr. Anita SchmittProf. Dr. Michael SchmittDr. Lei WangMedizinische Klinik V (Hämatologie, Onkologie undRheumatologie), Universitätsklinikum Heidelberg
Sponsors Venue
Heidelberg Marriott Hotel
Vangerowstraße 1669115 Heidelberg
Train StationHeidelberg Main Train Station 0.8 km away from hotel
Bus StationBetriebshof 0.5 km away from hotel 3rd CELL THERAPY SYMPOSIUM
October 25 & 26, 2019
Heidelberg Marriott Hotel Vangerowstraße 16 69115 Heidelberg
Department of Medicine V (Hematology, Oncology and Rheumatology)
PLATINUM: 20.000,-
15.000,-
Gold: 5.000,-
Silver: 3.500,-
3.000,-
2.500,-
2.000,-
Bronze: 1.500,-
1.500,-
1.500,-
1.000,-
850,-
Dear colleagues,
Since our last Cell Therapy Symposium only one year haselapsed. Within this short period of time, tremendousprogress has been made in our clinic regarding CAR T cellstherapy: more than thirty patients have received thisinnovative treatment. On the global level more than 2000patients have been treated for acute leukemia, Non-Hodgkin lymphoma and myeloma with remarkable success.Therefore the therapeutical algorithms for the treatment ofthese diseases need to be revisited. Moreover, the safemanagement of cytokine release syndrome, neurotoxicityand prolonged cytopenia will be highlighted in thissymposium. In addition, novel targets and preclinicalresearch for further development of immunogene therapywill be discussed.We are very proud to present a panel of speakers from themajor CAR T cell centers in Germany to give an update of thecurrent status. Also, we are very excited that we could winProf. Brenner from the Baylor’s College of Medicine,Houston/USA to give a key note lecture on his impressiveachievements in the field of immuno cell therapy.
We are looking forward to welcoming you to our symposium.
With very warm regards from Heidelberg
Michael Schmitt Carsten Müller-Tidow
Peter Dreger
The participation is free of charge.
The meeting has been certified from theLandesärztekammerand 9 CME points are granted.
To ensure proper organization, we welcome you toregister by short mail [email protected] October 1st, 2019.
Program – Day 1
12:00 Registration
13:00 Welcome addressCarsten Müller-Tidow / Michael Schmitt
Chairs:Carsten Müller-Tidow / Michael Schmitt
13:10 Status of the Heidelberg HD-CAR-1StudyMichael Schmitt
13:30 CART Real World: Experience withcommercial CARTs in HDPeter Dreger
13:50 CD70 and CD96 as novel targets forCAR T cell therapy in myeloid diseaseTim Sauer
14:10 Status of clinical CAR-T cell therapyand translation of the transposontechnique in IITs in WürzburgMichael Hudecek
14:30 Gene therapy for thalassemia patientsAndreas Kulozik
14:50 Automated cell processingArmin Rehm
15:10 Coffee break
Chairs:Tim Sauer / Sascha Dietrich
15:40 Practical side effect management inCAR-T cell therapyMaria-Luisa Schubert
16:00 Leukapheresis for CARs - status and regulatory affairsAnita Schmitt
16:20 BCMA CAR-T cells in myelomapatientsHartmut Goldschmidt
16:40 CAR-T cell production and therapy inTübingenPeter Lang
17:00 CAR-T cell therapy in KölnChristof Scheid
17:20 KEY NOTE: Houston News on CAR Tcell therapy and beyondMalcolm Brenner
18:15 End of Day 1
Program - Day 2
Chairs: Eric Gottwald / Maria-Luisa Schubert
09:00 CMV reactivation aftertransplantation of stem cells or CARsPatrick Derigs
09:20 Biomarkers for patients undergoingExtracorporeal PhotopheresisLei Wang
09:40 Status of clinical CAR-T cell therapy inMunichMarion Subklewe
10:00 Cord blood-banking: to what end?Patrick Wuchter
10:20 Novel CAR constructs for multiplemyelomaUta Höpken
10:40 Coffee break
Chairs:Anita Schmitt / Peter Dreger
11:10 CAR T cell culture in bioreactorsEric Gottwald
11:30 Which drugs should we add to CAR Tcell therapy?Sascha Dietrich
11:50 PRAME-TCR therapy of patients withAML/MDS or myelomaSimone Thomas
12:10 Closing Remarks/AdjournMichael Schmitt
12:30 End of Symposium